Treatment persistence, adherence and healthcare resource utilisation for <scp>iGlarLixi</scp> versus basal–bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: <scp>SoliEthnicity</scp> study
FRC therapies such as iGlarLixi represent an appropriate treatment option when intensifying basal insulin therapy in ethnic minority older adults with T2D.
Authors
- Guillermo E. Umpierrez (ORCID: https://orcid.org/0000-0002-3252-5026)
- Ana Núñez
- David A. Hood (ORCID: https://orcid.org/0000-0002-9553-152X)
- Xuan Li (ORCID: https://orcid.org/0000-0001-5781-1662)
- Jasvinder Gill
Institutions
- Emory University (US)
- Sanofi (United States) (US)
- University of Minnesota Medical Center (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1111/dom.16075
- Citations
- 1
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.36
Funders
- Sanofi